Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Beyond Diabetes: Exploring the Potential of GLP-1 Receptor Agonists in Neurodegenerative Disease Management

Medically reviewed by 
Beyond Diabetes: Exploring the Potential of GLP-1 Receptor Agonists in Neurodegenerative Disease Management

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of metabolic medications primarily used to treat type 2 diabetes mellitus and obesity. Recent studies have also shown the promising potential of GLP-1 receptor agonists in treating neurodegenerative diseases, including Alzheimer's and Parkinson's. 

This article discusses the role of insulin resistance in different forms of dementia and the neuroprotective effects of GLP-1 receptor agonists. 

Several main consequences of insulin resistance in the brain include damage to neurons and increased neuroinflammation. GLP-1 receptor agonists offer a potential new treatment modality for various dementias and other neurodegenerative conditions by improving neuronal survival, reducing inflammation, and enhancing metabolism. 


GLP-1 Receptor Agonists: From Diabetes to Neurodegeneration

Glucagon-like peptide-1 (GLP-1) is a neurohormone released from the intestines in response to oral intake. GLP-1 promotes increased glucose uptake into organs and tissues to regulate blood sugar. It also reduces glucose breakdown from the liver and other tissues, delays gastric emptying, and promotes fullness, thus reducing appetite. 

By binding to GLP-1 receptors, GLP-1 receptor agonists improve insulin sensitivity and blood glucose control. 

While dementia was once considered a common byproduct of aging, research now suggests it is linked to various diseases. One of the strongest links being studied is that of insulin resistance with dementia and neurodegenerative disorders. 

Because the cellular changes that occur in both insulin resistance and dementia are so similar, dementia has been termed "type 3 diabetes" and "insulin resistance of the brain." (GLP-1) receptor agonists are being studied in the treatment of neurodegenerative disorders given their ability to help regulate blood sugar levels, improve cellular insulin response, and maintain optimal body weight.

Mechanisms of Action in Neurodegeneration

GLP-1 receptor agonists show multifaceted neuroprotective effects in Alzheimer's disease. They promote neuronal growth, increase synaptic plasticity, and improve neuronal survival. Greater expression of insulin-degrading enzyme (IDe) is required for amyloid-beta degradation. 

GLP-1 receptor agonists have also been shown to reduce the buildup of amyloid-beta plaques by increasing their clearance.

The effects on Alzheimer's disease extend to inhibiting tau protein buildup by modulating the activity of an enzyme called glycogen synthase kinase-3β (GSK-3β).

Additional notable effects of GLP-1 receptor agonists include their potent anti-inflammatory and antioxidant properties, which directly reduce the neuroinflammation and oxidative stress that underlie neurodegenerative diseases. 

They suppress microglial activation and inflammatory cytokine release while simultaneously stimulating antioxidant enzymes, attenuating neuron damage.

Just as GLP-1 agonists improve insulin sensitivity in peripheral tissues, they also improve insulin sensitivity in the brain by restoring insulin signaling pathways required for neuronal glucose metabolism and synaptic function. GLP-1 agonists reduce the risk of neurodegenerative diseases by improving brain insulin sensitivity.

Research Highlights and Clinical Trials

The potential therapeutic effects of GLP-1 receptor agonists in Alzheimer's disease are well studied. The benefits include improvements in cognitive function and reductions in amyloid-beta and tau plaque deposition. 

In Parkinson's disease, GLP-1 receptor agonists reduce neuroinflammation and oxidative stress. Evidence suggests this leads to several benefits, including protection against neuronal destruction, preservation of dopamine, improvement in motor symptoms, and enhancement of overall quality of life. 

While much of the research on GLP-1 receptor agonists has focused on Alzheimer's and Parkinson's diseases, they may also have therapeutic potential in other neurodegenerative conditions. 

Ongoing research is investigating the use of GLP-1 agonists in Huntington's disease, potentially reducing neuronal dysfunction and neuroinflammation. Other studies are looking into the utility of GLP-1 agonists in amyotrophic lateral sclerosis (ALS).

Challenges and Considerations

Delivering GLP-1 receptor agonists to the brain is limited by the blood-brain barrier (BBB), the selectively permeable membrane that controls the passage of molecules from the bloodstream into the brain. GLP-1 agonists are large peptides precluded from effectively passing through the BBB. 

Different methodologies are being investigated, including chemical modifications to the drugs, smaller, nanoparticle-based delivery vehicles, and even ways to transiently disrupt the blood-brain barrier, such as focused ultrasound, which would increase the brain’s uptake of the drugs.

Safety is another concern with GLP-1 receptor agonists in patients with neurodegenerative diseases, as studies of their use in these patient populations are limited. 

Adverse effects like drug-drug interactions, hypoglycemia, and gastrointestinal upset could be more significant in patients with neurodegenerative diseases. Monitoring for adverse events and using individualized treatment approaches is crucial.

Future Directions and Clinical Implications

Ongoing efforts are underway to enhance the efficacy and deliverability of GLP-1 receptor agonists in treating neurodegenerative diseases. Novel formulations and alternative delivery methods are under investigation to improve their pharmacokinetics and brain penetration. 

To optimize the distribution of GLP-1 receptor agonists within the brain, sustained-release formulations, intranasal delivery systems, and specific nanoparticle-based vehicles are being studied. Additionally, efforts are underway to develop small-molecule GLP-1 receptor agonists with enhanced BBB permeability and improved therapeutic profiles.

The incorporation of GLP-1 receptor agonists into regular clinical practice in the treatment of Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases has a promising future. 

However, to ensure optimal patient outcomes, multispecialty collaboration among neurologists, endocrinologists, pharmacists, dietitians, and other metabolic health specialists will be required. 

Personalized medicine approaches will be essential to tailor treatment strategies based on individual patient factors, disease control, tolerance, and benefit while closely monitoring for adverse effects and long-term safety. 


Key Takeaways

  • Because insulin resistance is strongly linked to dementia and neurodegenerative disorders, recent studies have shown the promising potential of GLP-1 receptor agonists in their treatment. 
  • GLP-1 receptor agonists are being explored to treat neurological disorders by improving insulin resistance in the brain, enhancing glucose delivery and uptake, augmenting insulin signaling, and exerting potent anti-inflammatory effects. 
  • Ongoing research is needed to enhance their delivery to the central nervous system and ensure their safety and efficacy.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.
  1. Arif WM, Elsinga PH, Gasca-Salas C, et al. Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. J Control Release. 2020;324:303-316.
  2. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168–181.
  3. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123(6):2730-2736.
  4. Batista AF, Forny-Germano L, Clarke JR, et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. J Pathol. 2018;245(1):85–100.
  5. Baviera M, Foresta A, Colacioppo P, et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol. 2022;21(1):162.
  6. Bi Z, Wang L, Wang W. Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer's disease: A systematic review and meta-analysis. Adv Clin Exp Med. 2023;32(11):1223–1231.
  7. Blake, K. (2023, November 14). Integrative Strategies for Neurodegenerative Disease Management. Rupa Health.
  8. Buller S, Blouet C. Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss. Am J Physiol Endocrinol Metab. 2024;326(4):E472–E480.
  9. Chang CC, Lin TC, Ho HL, et al. GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. Int J Mol Sci. 2018;19(9):2505.
  10. Creedon, K. (2022, April 22). Integrative Strategies for Neurodegenerative Disease Management. Rupa Health.
  11. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11(3-4):202–230.
  12. Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221(1):T31-T41.
  13. Kabahizi A, Wallace B, Lieu L, et al. Glucagon-like peptide-1 (GLP-1) signaling in the brain: From neural circuits and metabolism to therapeutics. Br J Pharmacol. 2022;179(4):600–624.
  14. Lee, S. (2024, February 9). What Are GLP-1 Drugs, and Why Are They Becoming Popular? Rupa Health.
  15. Khakham, C. (2023, May 23). An Integrative Medicine Approach to Alzheimer’s Disease: Testing, Nutrition, and Supplements. Rupa Health.
  16. Long-Smith CM, Manning S, McClean PL, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signaling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med. 2013;15(1):102–114.
  17. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
  18. Shandilya A, Mehan S. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurol Sci. 2021;42(8):3145–3166.
  19. Stanford, J. (2024, March 4). Is Dementia Actually Type 3 Diabetes? The Role of Insulin Resistance. Rupa Health.
  20. Sweetnich, J. (2023, April 25). Complementary and Integrative Medicine Approaches to Type 2 Diabetes Management. Rupa Health.
  21. Yoshimura, H. (2023, November 13). Guarding Your Health: Proactive Steps to Ward Off Insulin Resistance. Rupa Health.
  22. Yoshimura, H. (2023, June 12). What Is the Link Between Diabetes and Alzheimer's Disease? Rupa Health.
  23. Yoshimura, H. (2023, July 17.) Using Functional Medicine as Personalized Medicine. Rupa Health.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.